Getinge said Tuesday it will phase out its surgical perfusion business and reallocate resources to higher-growth areas such as extracorporeal membrane oxygenation (ECMO) and transplant care. CEO ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S. (Reuters) ...

Narrow-moat Getinge GETI B reported third-quarter earnings above our expectations. We are increasing our fair value estimate to SEK 247 from SEK 221, as Getinge is executing a turnaround in its acute ...

GOTHENBURG, Sweden, Sept. 30, 2020 /PRNewswire/ -- Born 12 weeks too early with a 50/50 chance at survival, Sabina Checketts has grown up to become a neonatal doctor herself, using new therapies and ...

GÖTEBORG, Sweden, July 24, 2020 /PRNewswire/ -- Today Getinge announces its intention to become a CO₂neutral company by 2025. The target will be reached by a stepwise approach in several areas and ...

Getinge’s GETI B recent litany of regulatory, quality, and supply chain troubles across multiple products provides us with a flashback to 2013-2015 when similar issues culminated in a consent decree ...

Price hikes and cost saving measures aid Getinge's earnings growth Absorbs chunk of near-term tariff costs before pricing measures fully bite US probe into medtech imports doesn't affect Getinge, CEO ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

The acquisition is expected to close in the third quarter of this year, and Getinge said it’s not expecting the purchase to have a material impact on its bottom line in 2023, nor will it add any ...

GETINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Getinge Group (STO:GETIB) has recently performed a strategic review to clarify its long-term strategy for ensuring sustainable and profitable growth.

* GETINGE CEO: NORMALISATION IN CHINA IS SLOWLY BUT SURELY HAPPENING AFTER COVID BUT WE DON'T SEE A STRONG RECOVERY OR STRONG POSITIVE IMPACT YET * GETINGE CEO: WE EXPECT MIXED PERFORMANCE FROM CHINA ...